Clinical and Radiologic Predictors of Response to Atezolizumab-Bevacizumab in Advanced Hepatocellular Carcinoma
Cancer Research and Treatment · 15.10.2024 · 56 (4) · 1219-1230
DOI: 10.4143/crt.2024.283 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Research and Treatment, erschienen am 15.10.2024. Verfasst von Se Jin Choi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Bevacizumab, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Purpose
This study aimed to identify clinical and radiologic characteristics that could predict response to atezolizumab-bevacizumab combination therapy in patients with advanced hepatocellular carcinoma (HCC).Materials and Methods This single-center retrospective study included 108 advanced HCC patients with intrahepatic lesions who were treated with atezolizumab-bevacizumab. Two radiologists independently analyzed imaging characteristics of the index tumor on pretreatment computed tomography. Predictive factors associated with progressive disease (PD) at the best response based on Response Evaluation Criteria in Solid Tumors, ver. 1.1 were evaluated using logistic regression analysis. Progression-free survival (PFS) was estimated by the Kaplan-Meier method and compared with the log-rank test.
Results
Of 108 patients with a median PFS of 15 weeks, 40 (37.0%) had PD during treatment. Factors associated with PD included the presence of extrahepatic metastases (adjusted odds ratio [aOR], 4.13; 95% confidence interval [CI], 1.19 to 14.35; p=0.03), the infiltrative appearance of the tumor (aOR, 3.07; 95% CI, 1.05 to 8.93; p=0.04), and the absence of arterial-phase hyperenhancement (APHE) (aOR, 6.34; 95% CI, 2.18 to 18.47; p < 0.001). Patients with two or more of these factors had a PD of 66.7% and a median PFS of 8 weeks, indicating a significantly worse outcome compared to the patients with one or no of these factors.
Conclusion
In patients with advanced HCC treated with atezolizumab-bevacizumab treatment, the absence of APHE, infiltrative appearance of the intrahepatic tumor, and presence of extrahepatic metastases were associated with poor response and survival. Evaluation of early response may be necessary in patients with these factors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Zitieren
APA
Choi, S. J., Chung, S. W., Choi, J., Kim, K. M., Kim, H. D., Yoo, C., Ryoo, B. Y., Lee, S. S., Choi, W. M., & Choi, S. H. (2024). Clinical and Radiologic Predictors of Response to Atezolizumab-Bevacizumab in Advanced Hepatocellular Carcinoma. Cancer Research and Treatment, 56(4), 1219-1230. https://doi.org/10.4143/crt.2024.283
Vancouver
Choi SJ, Chung SW, Choi J, Kim KM, Kim HD, Yoo C, et al. Clinical and Radiologic Predictors of Response to Atezolizumab-Bevacizumab in Advanced Hepatocellular Carcinoma. Cancer Research and Treatment. 2024;56(4):1219-1230. doi:10.4143/crt.2024.283
BibTeX
@article{Choi2024,
author = {Choi, Se Jin and Chung, Sung Won and Choi, Jonggi and Kim, Kang Mo and Kim, Hyung-Don and Yoo, Changhoon and Ryoo, Baek-Yeol and Lee, Seung Soo and Choi, Won-Mook and Choi, Sang Hyun},
title = {Clinical and Radiologic Predictors of Response to Atezolizumab-Bevacizumab in Advanced Hepatocellular Carcinoma},
journal = {Cancer Research and Treatment},
year = {2024},
volume = {56},
number = {4},
pages = {1219--1230},
doi = {10.4143/crt.2024.283}
}
EUVIMED